Elite in Non-Small Cell Lung Cancer (NCSLC)
Check Dr. Anne S. Tsao's experience treating your condition:
About Dr. Anne S. Tsao

Anne Tsao is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Tsao has been practicing medicine for over 24 years and is rated as an Elite expert by MediFind in the treatment of Non-Small Cell Lung Cancer (NCSLC). She is also highly rated in 16 other conditions, according to our data. Her top areas of expertise are Malignant Mesothelioma, Lung Cancer, Metastatic Pleural Tumor, and Non-Small Cell Lung Cancer (NCSLC). She is licensed to treat patients in Texas. Tsao is currently accepting new patients.

Her clinical research consists of co-authoring 122 peer reviewed articles and participating in 28 clinical trials in the past 15 years. In particular, she has co-authored 48 articles and participated in 8 clinical trials in the study of Non-Small Cell Lung Cancer (NCSLC).


MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Anne S. Tsao it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
1515 Holcombe Blvd, 30 Unit Number 4, Houston, TX 77030
Background & Education
Graduate Institution
University Of Chicago, Pritzker School Of Medicine, 1998
Hematology Oncology
Internal Medicine in TX
Hospital Affiliations
University Of Texas MD Anderson Cancer Center
Languages Spoken
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Pilot Trial of Ipilimumab-Nivolumab in Local-Regionally Advanced Non Small Cell Lung Cancer (NSCLC)
An Open-label, Multi-center, Phase I Study of Oral IAG933 in Adult Patients With Advanced Mesothelioma and Other Solid Tumors
Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma
A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma
A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Phase II Study of Imatinib Mesylate and Docetaxel in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma
A Phase II, Open Label Study of ZD6474 in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase I Trial of Induction Dasatinib Therapy in Patients With Resectable Malignant Pleural Mesothelioma
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
View 13 Less Clinical Trials -

Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
Learn about our expert tiers
Learn more
Similar Doctors